Today: 7 July 2026

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Meta stock edges higher after nuclear power deals aimed at AI data centers

Meta stock edges higher after nuclear power deals aimed at AI data centers

NEW YORK, January 9, 2026, 16:30 EST — After-hours Meta Platforms, Inc. shares rose 1.1% to $653.06 in after-hours trading on Friday after the Facebook owner unveiled a slate of nuclear power agreements meant to supply its power-hungry AI data centers. Meta said deals with Vistra, Oklo and TerraPower could back as much as 6.6 gigawatts of new and existing nuclear capacity by 2035.
9 January 2026
······
Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon.com shares rose 0.4% in after-hours trading on Friday after Amazon Pharmacy said it has begun offering Novo Nordisk’s Wegovy weight-loss pill via insurance plans as well as a cash-pay option. Customers who qualify and have commercial insurance could pay $25 for a one-month supply, while cash-pay begins at $149; the U.S. FDA approved the pill in December, Amazon said. AMZN last traded at $247.33, after ranging from $242.31 to $247.71 during the session. Novo has said the pill will also be available through CVS and Costco and through telehealth providers including Ro, LifeMD, WeightWatchers and GoodRx. It’s a notable step as Amazon keeps leaning further into healthcare, with GLP-1 weight-loss drugs now driving demand — and sparking plenty of argument over who covers the cost. Wegovy is a GLP-1 drug, a class of medicines that mimics a gut hormone to help people feel full, and a pill version could appeal to patients who don’t want injections.
9 January 2026
····
Sandisk stock jumps on report of possible enterprise NAND price doubling — what’s next for SNDK

Sandisk stock jumps on report of possible enterprise NAND price doubling — what’s next for SNDK

New York, January 9, 2026, 16:19 — After-hours Sandisk climbed 12.8% to $377.41 in after-hours trading on Friday after a report said the flash-memory maker could more than double prices for some high-capacity 3D NAND chips used in enterprise solid-state drives. Nomura Securities said “channel checks” showed enterprise-grade NAND pricing was seeing “especially aggressive increases,” with Sandisk’s enterprise NAND cited as rising more than 100% from the prior quarter. The stock traded between $330.96 and $383.76 during the session, with about 19.2 million shares changing hands.
9 January 2026
···
1 … 528 529 530 531 532 … 879

Stock Market Today

  • DAIHEN Board to Review Treasury Stock Awards, More Pressure on Valuation
    July 7, 2026, 4:50 AM EDT. DAIHEN (TSE:6622) has put a board meeting on the calendar for June 24, 2026, to look at a plan using treasury shares for executive restricted stock awards that would link pay to share price. The stock last traded at ¥17,160, giving it a 28.7x P/E-well above an industry average of 14.5x and peers at 20.8x. Earnings are growing at 6.3% a year, with the latest period showing an 18% jump, but return on equity is only 9.2%. Investors are paying up on hopes for growth, but discounted cash flow estimates say the stock might be expensive. The board's review is drawing more attention to dilution risk and how DAIHEN is handling capital after a strong run for the shares.
Go toTop